Neutral



Jyothy Laboratories

Estimate change

TP change

Rating change

Bloomberg	JYL IN
Equity Shares (m)	367
M.Cap.(INRb)/(USDb)	201.1 / 2.4
52-Week Range (INR)	574 / 243
1, 6, 12 Rel. Per (%)	28/-14/64
12M Avg Val (INR M)	599

Financials & Valuations (INR b)

	- 1	- /	
Y/E March	2024	2025E	2026E
Net Sales	27.6	30.2	33.4
Sales Gr. (%)	10.9	9.6	10.6
EBITDA	4.8	5.4	6.0
EBITDA Margins (%)	17.4	17.9	18.1
Adj PAT	3.6	4.1	4.6
Adj. EPS (INR)	9.8	11.1	12.4
EPS Gr. (%)	54.8	12.8	12.3
BV/Sh (INR)	49.2	52.1	58.0
Ratios			
RoE (%)	21.5	21.8	22.6
RoCE (%)	21.1	21.4	22.8
Payout (%)	43.2	59.0	52.6
Valuation			
P/E (x)	48.6	43.1	38.4
P/BV (x)	9.7	9.2	8.2
EV/EBITDA	36.0	31.5	27.8
Div. Yield (%)	0.7	1.1	1.1

Shareholding pattern (%)

As On	Jun-24	Mar-24	Jun-23
Promoter	62.9	62.9	62.9
DII	14.4	13.3	15.4
FII	15.1	16.4	14.0
Others	7.7	7.4	7.8

FII Includes depository receipts

In-line performance; focus on volume-driven growth

CMP: INR548

TP: INR565 (+3%)

- Jyothy Laboratories (JYL) reported a revenue growth of 8% YoY (in line) in 1QFY25. It delivered a volume growth of 11% and continued to focus on volume-led growth to gain market share across categories. The company is not expecting price hike-led growth in FY25.
- Fabric care delivered 9% growth, with growth from both main-wash and post-wash categories. Dish-wash growth stood at 7% YoY, led by LUPs. Exo's market share in the eastern region increased from low-single digits to double digits. HI grew 2% YoY only, hurt by the extended and harsh summer. Personal care was weaker than expected, clocking 11% YoY growth (vs. ~21% growth in FY24).
- Gross margin (GM) was up 340bp YoY to 51.3%, at an all-time high led by the mix, lower RM costs, and better sourcing. EBITDA margin inched up 90bp YoY to 18%. EBITDA grew 14% YoY during the quarter, on a high base (~96% EBITDA growth in 1QFY24), and a five-year CAGR is 15%.
- We model a 10%/12% revenue/EBITDA CAGR over FY24-26E. With a stable RM basket, we expect the EBITDA margin to be ~18%.
- We believe that the margin-led growth will be normalized in FY25. From here on, market share gains and the success of new launches will be critical for JYL's earnings growth. Due to its expensive valuations, we reiterate our Neutral rating on the stock with a TP of INR565 (premised on 45x Jun'26E P/E).

Overall in-line quarter; volume growth stood at 11% YoY

- Sales growth across segments: JYL registered a net sales growth of 8% YoY to INR7,418m (est. INR7,524m). Volume growth was 10.8% YoY (est. 9.0%) in 1QFY25. The Fabric care/Dish-wash/HI/Personal care sales grew 9%/7%/2%/11% YoY to INR3,228m/INR2,480m/INR503m/INR932m in 1QFY25. The four-year CAGR for Fabric care stood at 23%, while Dish wash and Personal care CAGR stood at +12% each. HI declined 6%.
- Improvement in margins: Gross margin expanded ~340bp/180bp YoY/QoQ to 51.3% (est. 48.5%). As a percentage of sales, staff costs rose 60bp YoY to 11.6%, ad spending increased 100bp YoY to 8.3%, and other expenses grew 100bp YoY to 13.4%. EBITDA margin expanded 90bp YoY to 18.0%. (est. 17.5%).
- Segmental profitability: EBIT margins in the Fabric care/Household Insecticide segments expanded 270bp/820bp YoY to 24.9%/(10.8%), while Personal care margin contracted 730bp YoY to 11%. Dish-wash's EBIT margin was stable at 20% in 1QFY25.
- **Double-digit growth**: EBITDA grew 14% YoY to INR1,335m (est. of INR1,317m). PBT grew 18% YoY to INR1,324m (est. INR1,269m). Adj. PAT increased 17% YoY to INR1,017m (est. INR977m).

Naveen Trivedi – Research Analyst (Naveen.Trivedi@MotilalOswal.com)

Research Analyst: Pratik Prajapati (Pratik.Prajapati@MotilalOswal.com) | Tanu Jindal (Tanu.Jindal@MotilalOswal.com)

MOTILAL OSWAL Jyothy Laboratories

Highlights from the management commentary

- Demand is likely to accelerate with normal monsoons. Rural demand pickup is key for positive momentum.
- JYL delivered 11% YoY volume growth during the quarter. The value-volume gap is due to the increase in grammages and price cuts taken by the company.
- The contributions of modern trade and e-commerce to revenue have increased to 15%, up from 10% two to three years ago.
- Capex will be INR500-600m in FY25. Cash balance is over INR6.5b at the end of 1QFY25.

Valuation and view

- There are no material changes to our EPS estimates for FY25 and FY26.
- We believe that the margin-led growth will be normalized in FY25. From here on, market share gains and the success of new launches will be critical for JYL's earnings growth. JYL's margin expansion beyond ~18% is also constrained by its focus on the mass and rural segments. Therefore, we believe its growth potential is adequately priced-in at the current valuation. We reiterate our Neutral rating on the stock with a TP of INR565 (premised on 45x Jun'26E P/E).

Consolidated quarterly performance (INR m											(INR m)	
Y/E March		FY2	4			FY25	E				FY25	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY24	FY25E	1QE	(%)
Net Sales	6,871	7,323	6,775	6,600	7,418	8,056	7,453	7,287	27,569	30,213	7,524	-1.4
YoY change (%)	15.1	11.1	10.6	7.0	8.0	10.0	10.0	10.4	10.9	9.6	9.5	
Gross Profit	3,289	3,604	3,371	3,267	3,805	4,108	3,801	3,695	13,531	15,409	3,649	4.3
Margins (%)	47.9	49.2	49.8	49.5	51.3	51.0	51.0	50.7	49.1	51.0	48.5	
EBITDA	1,174	1,354	1,186	1,084	1,335	1,530	1,312	1,222	4,798	5,398	1,317	1.4
EBITDA growth %	96.2	68.3	40.6	18.7	13.7	13.0	10.6	12.8	51.9	12.5	12.1	
Margins (%)	17.1	18.5	17.5	16.4	18.0	19.0	17.6	16.8	17.4	17.9	17.5	
Depreciation	120	123	128	129	134	130	136	134	500	535	132	
Interest	11	12	12	13	14	13	13	13	47	52	12	
Other Income	79	132	106	130	137	130	125	108	447	500	95	
PBT	1,123	1,351	1,152	1,072	1,324	1,517	1,288	1,183	4,698	5,312	1,269	4.3
Tax	250	311	243	291	307	355	301	285	1,095	1,248	292	
Rate (%)	22.3	23.0	21.1	27.1	23.2	23.4	23.4	24.1	23.3	23.5	23.0	
Adjusted PAT	873	1,040	909	781	1,017	1,162	986	898	3,603	4,064	977	4.1
YoY change (%)	124.1	78.2	34.9	31.9	16.6	11.8	8.5	14.9	54.8	12.8	12.0	

E: MOFSL Estimates

Key performance indicators

Y/E March		FY24	l .			FY25		
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE
2Y average growth %								
Sales	14.7	12.5	13.2	10.0	11.5	10.5	10.3	8.7
EBITDA	44.1	44.1	40.0	39.0	54.9	40.7	25.6	15.8
PAT	60.6	58.4	62.6	54.9	70.3	45.0	21.7	23.4
% sales								
COGS	52.1	50.8	50.2	50.5	48.7	49.0	49.0	49.3
Other expenditure	30.8	30.7	32.3	33.1	33.3	32.0	33.4	33.9
Depreciation	1.7	1.7	1.9	1.9	1.8	1.6	1.8	1.8
YoY change %								
COGS	-0.3	-5.2	-2.4	-0.5	0.9	6.1	7.3	7.8
Other expenditure	18.7	20.6	21.6	14.4	16.8	14.6	13.9	13.3
Other income	80.0	147.8	-30.6	127.5	72.8	-1.7	18.0	-16.9
EBIT	125.2	82.6	46.5	20.4	13.8	13.8	11.1	13.9

E: MOFSL Estimates



Highlights from the management commentary

Performance and outlook

- Demand is expected to accelerate with normal monsoons. Rural demand pickup is key for positive momentum.
- JYL delivered 11% volume growth and continued focus on volume-led growth to gain higher market share for each brands.
- The value-volume gap is due to the increase in grammages and price cuts taken by the company.
- Price cuts were taken across segments, with the most significant reductions in dish-wash, followed by Fabric care, and then Personal care.
- JYL is not expecting any price hike in FY25.
- The company focuses on rural distribution, innovation, and introduction of SKU's to cater to specific consumer segments.
- The contributions of modern trade and e-commerce to revenue have increased to 15%, up from 10% two to three years ago.

Costs and margins

- Management guided double-digit sales growth mainly led by volume.
- The gross margin expanded due to a more favorable product mix and improved operational efficiencies.
- It maintains an EBITDA guidance of 16-17% for FY25.

Segmental details

Fabric care

- It delivered 9% sales growth in 1QFY25.
- Distribution, ground-level activities, and product differentiation helps in faster growth and expansion across product categories.
- The company launched More Light 5L liquid detergent pouch during the quarter at reasonable price of INR70/L.
- The liquid category will grow faster on a low base compared to powder.

Dish wash

- It delivered 7% sales growth in 1QFY25.
- JYL will continue to enhance the brand equity by driving LUP's, enhanced digital awareness, ground activations to strengthen their position.
- Pril larger packs gaining momentum in MT. Pril Tamarind delivered continuously delivered strong double-digit growth.
- Exo has 13.8% market share in dish wash bar and Pril has 14.4% market share in dish wash liquids.
- Exo's market share in the eastern region increased from low single digits to double digits.

Household Insecticides

- The sales increased 2% YoY in 1QFY25. The category has been hit by summer in North and Fast India
- Strengthening the liquid portfolio by focusing on continued brand investment, and emphasizing the unique automatic feature of the Maxo machine.
- Maxo Coil and liquid vaporizer market share stood at 25.8% and 9.1%.

Personal Care

- It delivered 11% sales growth in 1QFY25.
- Neem-based Margo Soap with its natural benefits proposition delivered a double-digit growth.
- Strengthening the brand equity of Margo to venture into new formats and categories.

Other points

- Capex will be INR0.5-0.6b for FY25.
- Cash balance is over INR6.5b at the end of 1QFY25.

Key exhibits

Exhibit 1: Consolidated quarterly performance

Eximple 1: Consolidated quarte									
Sales (INR m)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25
Fabric Care	2,511	2,862	2,635	2,553	2,966	3,166	2,948	2,811	3,228
Dishwashing	2,093	2,279	2,213	2,062	2,315	2,507	2,361	2,183	2,480
Household Insecticides	448	435	434	800	494	450	457	722	503
Personal Care	694	733	591	524	841	896	723	618	932
Other Products	225	284	253	230	256	304	286	266	274
Total	5,972	6,592	6,127	6,170	6,871	7,323	6,775	6,600	7,418
Sales salience (%)									
Fabric Care	42	43	43	41	43	43	44	43	44
Dishwashing	35	35	36	33	34	34	35	33	33
Household Insecticides	8	7	7	13	7	6	7	11	7
Personal Care	12	11	10	8	12	12	11	9	13
Other Products	4	4	4	4	4	4	4	4	4
Total	100	100	100	100	100	100	100	100	100
Sales growth (%)									
Fabric Care	39	34	26	20	18	11	12	10	9
Dishwashing	10	6	10	9	11	10	7	6	7
Household Insecticides	(38)	(31)	(16)	1	10	3	5	(10)	2
Personal Care	2	11	12	12	21	22	22	18	11
Other Products	68	7	4	26	14	7	13	16	7
Total	14	13	14	13	15	11	11	7	8
EBIT (INR m)									
Fabric Care	308	433	485	499	656	828	744	647	802
Dishwashing	275	352	338	361	463	523	425	393	495
Household Insecticides	(45)	(79)	(69)	(9)	(94)	(79)	(93)	(75)	(54)
Personal Care	25	74	90	70	153	98	93	52	103
Other Products	(10)	(15)	(15)	(8)	5	1	15	(3)	(5)
Total	554	765	830	912	1,184	1,370	1,183	1,014	1,341
EBIT salience (%)					-	-	-		
Fabric Care	56	57	58	55	55	60	63	64	60
Dishwashing	50	46	41	40	39	38	36	39	37
Household Insecticides	(8)	(10)	(8)	(1)	(8)	(6)	(8)	(7)	(4)
Personal Care	4	10	11	8	13	7	8	5	8
Other Products	(2)	(2)	(2)	(1)	0	0	1	(0)	(0)
Total	100	100	100	100	100	100	100	100	100
EBIT margin (%)									
Fabric Care	12.3	15.1	18.4	19.5	22.1	26.1	25.2	23.0	24.9
Dishwashing	13.2	15.4	15.3	17.5	20.0	20.9	18.0	18.0	20.0
Household Insecticides	(10.0)	(18.2)	(15.9)	(1.2)	(19.0)	(17.6)	(20.4)	(10.4)	(10.8)
Personal Care	3.6	10.1	15.3	13.3	18.2	10.9	12.9	8.5	11.0
Other Products	(4.4)	(5.3)	(6.1)	(3.5)	1.9	0.2	5.3	(1.1)	(1.6)
Total	9.3	11.6	13.5	14.8	17.2	18.7	17.5	15.4	18.1


Source: Company, MOFSL


Valuation and view

- There are no material changes to our EPS estimates for FY25 and FY26.
- We believe that the margin-led growth will be normalized in FY25. From here on, market share gains and the success of new launches will be critical for JYL's earnings growth. JYL's margin expansion beyond ~18% is also constrained by its focus on the mass and rural segments. Therefore, we believe its growth potential is adequately priced-in at the current valuation. We reiterate our Neutral rating on the stock with a TP of INR565 (premised on 45x Jun'26E P/E).

Exhibit 2: No material changes to our estimation for FY25/FY26

	New		0	ld	Change (%)		
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	
Sales	30,213	33,428	30,319	33,561	-0.3%	-0.4%	
EBITDA	5,398	6,041	5,323	5,972	1.4%	1.2%	
PAT	4,064	4,563	3,999	4,492	1.6%	1.6%	





Source: Company, MOFSL

MOTILAL OSWAL Jyothy Laboratories

Financials and valuations

Consolidated - Income Statement									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Total Income from Operations	18,136	17,112	19,091	21,965	24,860	27,569	30,213	33,428	36,766
Change (%)	8.4	-5.6	11.6	15.1	13.2	10.9	9.6	10.6	10.0
Cost of Materials Consumed	9,707	9,009	10,104	12,830	14,349	14,038	14,804	16,346	17,942
As a percentage of Sales	53.5	52.6	52.9	58.4	57.7	50.9	49.0	48.9	48.8
Gross Profit	8,429	8,103	8,987	9,135	10,511	13,531	15,409	17,082	18,824
Margin (%)	46.5	47.4	47.1	41.6	42.3	49.1	51.0	51.1	51.2
EBITDA	2,811	2,511	3,145	2,482	3,159	4,798	5,398	6,041	6,638
Margin (%)	15.5	14.7	16.5	11.3	12.7	17.4	17.9	18.1	18.1
Depreciation	306	529	556	582	501	500	535	572	612
EBIT	2,505	1,982	2,589	1,901	2,657	4,298	4,864	5,469	6,026
Int. and Finance Charges	352	329	192	118	131	47	52	55	57
Other Income	278	203	185	187	395	447	500	550	625
PBT bef. EO Exp.	2,430	1,856	2,581	1,969	2,922	4,698	5,312	5,964	6,594
EO Items	0	-38	-235	0	70	90	0	0	0
PBT after EO Exp.	2,430	1,818	2,346	1,969	2,992	4,788	5,312	5,964	6,594
Current Tax	454	189	440	378	595	1,095	1,248	1,402	1,550
Tax Rate (%)	18.7	10.4	18.7	19.2	19.9	22.9	23.5	23.5	23.5
Reported PAT	2,051	1,706	1,994	1,620	2,397	3,695	4,064	4,563	5,044
Adjusted PAT	1,976	1,667	2,142	1,591	2,327	3,603	4,064	4,563	5,044
Change (%)	10.5	-15.6	28.5	-25.7	46.2	54.8	12.8	12.3	10.6
Margin (%)	10.9	9.7	11.2	7.2	9.4	13.1	13.4	13.6	13.7

Consolidated - Balance Sheet									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	367	367	367	367	367	367	367	367	367
Total Reserves	12,898	11,919	13,918	14,068	15,123	17,716	18,775	20,938	23,583
Net Worth	13,265	12,286	14,286	14,435	15,490	18,083	19,142	21,305	23,950
Minority Interest	-215	-291	-379	-407	21	19	19	19	19
Deferred Liabilities	-928	-1,027	-962	-907	-845	-594	-594	-594	-594
Total Loans	2,809	2,830	1,169	1,265	0	1,062	0	0	0
Capital Employed	14,932	13,798	14,114	14,387	14,665	18,570	18,567	20,730	23,375
Gross Block	12,046	13,050	13,556	13,764	14,125	13,715	14,215	14,415	14,615
Less: Accum. Deprn.	1,040	1,558	2,089	2,546	2,962	2,462	2,997	3,569	4,181
Net Fixed Assets	11,006	11,492	11,467	11,218	11,163	11,253	11,218	10,846	10,434
Capital WIP	143	245	101	76	155	134	123	123	123
Total Investments	1,044	0	0	0	0	1,915	1,915	1,915	1,915
Curr. Assets, Loans&Adv.	6,301	5,598	7,029	8,027	8,454	10,108	11,586	15,104	19,298
Inventory	1,974	2,251	2,786	2,972	3,019	2,835	4,230	4,680	5,147
Account Receivables	1,534	1,224	944	1,431	1,378	2,014	1,511	1,671	1,838
Cash and Bank Balance	964	289	1,938	2,112	2,835	1,661	3,002	5,607	8,852
Loans and Advances & Others	1,830	1,834	1,361	1,512	1,222	3,599	2,843	3,146	3,460
Curr. Liability & Prov.	3,563	3,537	4,483	4,933	5,107	4,840	6,275	7,258	8,395
Account Payables	2,134	1,450	2,143	2,364	2,143	2,761	3,021	3,343	3,677
Other Current Liabilities	715	1,299	1,520	1,767	2,037	1,756	2,196	2,745	3,432
Provisions	715	788	820	802	927	324	1,057	1,170	1,287
Net Current Assets	2,738	2,061	2,546	3,093	3,347	5,268	5,311	7,846	10,903
Appl. of Funds	14,932	13,798	14,114	14,387	14,665	18,570	18,567	20,730	23,375

E: MOFSL Estimates

Financials and valuations

Ratios									
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Basic (INR)									
EPS	5.4	4.5	5.8	4.3	6.3	9.8	11.1	12.4	13.7
Cash EPS	6.2	6.0	7.3	5.9	7.7	11.2	12.5	14.0	15.4
BV/Share	36.1	33.5	38.9	39.3	42.2	49.2	52.1	58.0	65.2
DPS	6.0	0.0	4.0	2.5	3.0	3.5	5.4	5.4	5.4
Payout (%)	134	0	83	70	57	43	59	53	48
Valuation (x)									
P/E	88.6	105.1	81.8	110.1	75.3	48.6	43.1	38.4	34.7
Cash P/E	76.8	79.8	64.9	80.6	61.9	42.7	38.1	34.1	31.0
P/BV	13.2	14.3	12.3	12.1	11.3	9.7	9.2	8.2	7.3
EV/Sales	9.7	10.4	9.1	7.9	6.9	6.3	5.6	5.0	4.5
EV/EBITDA	62.6	70.8	55.4	70.2	54.6	36.0	31.5	27.8	24.8
Dividend Yield (%)	1.3	0.0	0.8	0.5	0.6	0.7	1.1	1.1	1.1
FCF per share	7.2	3.5	10.3	4.9	8.6	2.7	13.5	12.3	13.8
Return Ratios (%)									
RoE	16.0	13.0	16.1	11.1	15.6	21.5	21.8	22.6	22.3
RoCE	13.7	12.6	14.7	10.8	15.7	21.1	21.4	22.8	22.5
RoIC	15.7	13.6	16.6	12.7	17.8	25.0	26.2	31.4	36.1
Working Capital Ratios									
Asset Turnover (x)	1.2	1.2	1.4	1.5	1.7	1.5	1.6	1.6	1.6
Inventory (Days)	39.7	48.0	53.3	49.4	44.3	37.5	51.1	51.1	51.1
Debtor (Days)	30.9	26.1	18.0	23.8	20.2	26.7	18.3	18.3	18.3
Creditor (Days)	80.2	58.7	77.4	67.3	54.5	71.8	74.5	74.6	74.8
Working Cap. Turnover (Days)	35.7	37.8	11.6	16.3	7.5	47.8	27.9	24.4	20.4
Leverage Ratio (x)									
Current Ratio	1.8	1.6	1.6	1.6	1.7	2.1	1.8	2.1	2.3
Interest Cover Ratio	7	6	13	16	20	91	93	100	105
Debt/Equity	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.0	0.0
Consolidated - Cash Flow Statement									(INR m)
Y/E March	FY19E	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	2,430	1,815	2,346	1,969	2,992	4,698	5,312	5,964	6,594
Depreciation	306	529	556	582	501	500	535	572	612
Interest & Finance Charges	314	304	161	82	54	47	52	55	57
Other income	-25	-21	232	-36	-197	-507	-500	-550	-625
Direct Taxes Paid	-418	-386	-327	-313	-567	-1,095	-1,248	-1,402	-1,550
(Inc)/Dec in WC	409	-527	1,055	-259	502	-3,095	1,299	70	189
CF from Operations	3,016	1,715	4,022	2,025	3,286	547	5,449	4,709	5,277
CF from Operating incl EO	3,016	1,715	4,022	2,025	3,286	547	5,449	4,709	5,277
(inc)/dec in FA	-383	-415	-257	-214	-122	432	-489	-200	-200
(Pur)/Sale of Investments	112	1,061	0	0	0	-1,915	0	0	0
Others	37	4	45	29	65	303	-105	550	625
CF from Investments	-234	650	-212	-185	-57	-1,181	-594	350	425
Issue of Shares	4	0	0	0	0	0	0	0	0
(Inc)/Dec in Debt	-610	41	-1,669	100	-1,250	1,062	-1,062	0	0
Interest Paid	-342	-212	-281	-74	-104	-47	-52	-55	-57
Dividend Paid	-182	-2,656	0	-1,469	-918	-1,555	-2,399	-2,399	-2,399
Others	-2,055	-211	-212	-224	-235	0	0	0	0
CF from Fin. Activity	-3,185	-3,039	-2,161	-1,667	-2,507	-540	-3,513	-2,454	-2,457
Inc/Dec of Cash	-403	-674	1,649	174	723	-1,174	1,341	2,605	3,245
Opening Balance	1,367	964	289	1,938	2,112	2,835	1,661	3,002	5,607
Closing Balance	964	289	1,938	2,112	2,835	1,661	3,002	5,607	8,852
E: MOESI Estimatos									

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

MOTILAL OSWAL Jyothy Laboratories

NOTES

Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	< - 10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage transactions. Details of pending Enquiry Proc llaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx Enquiry Proceedings Motilal Oswal Financial Services Limited available of are

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

Disclosures

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act 1934 act 1934) and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.raiani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

9 25 July 2024

MOTILAL OSWAL **Jyothy Laboratories**

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dogrievances@motilaloswal.com.

10 25 July 2024